Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity

PURPOSE: To evaluate refractive and structural outcomes for patients treated for retinopathy of prematurity (ROP) with the anti–vascular endothelial growth factor (anti-VEGF) agent ranibizumab and “delayed laser,” defined as any laser photocoagulation treatment administered at least 2 weeks and <...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoppe, Charis, Holt, Derick G., Arnold, Benjamin F., Thinda, Sumeer, Padmanabhan, Sriranjani P., Oatts, Julius T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020667/
https://www.ncbi.nlm.nih.gov/pubmed/36265750
http://dx.doi.org/10.1016/j.jaapos.2022.08.524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020667/
https://www.ncbi.nlm.nih.gov/pubmed/36265750
http://dx.doi.org/10.1016/j.jaapos.2022.08.524

Ejemplares similares